Objective:To investigate the relationship between expression of secreted protein acidic and rich in cysteine (SPARC) in hormone receptor (HR) -positive breast cancer tissues and clinicopathological characteristics and axillary lymph node metastasis.Methods:The clinical data of 202 patients with breast cancer in Shaanxi Provincial Cancer Hospital were retrospectively analyzed from Mar. 2021 to Mar. 2023. The expression of SPARC protein in the lesion tissues of all subjects at admission was detected by immunohistochemistry. On the basis of molecular typing, the patients were classified into HR-positive subgroup and non-HR-positive subgroup, and the difference in SPARC protein expression in the lesion tissues at admission was compared. According to the axillary lymph node metastasis status at 1 year of follow-up, patients with HR-positive breast cancer were assigned into metastasis group and non-metastasis group, and the expression of SPARC protein in the lesion tissues at admission was compared. HR-positive breast cancer patients were divided into positive group and negative group by means of the expression of SPARC protein at admission. The clinicopathological characteristics [age, tumor size, breast cancer TNM staging, vascular tumor thrombus, histological grading, estrogen receptor (ER), progesterone receptor (PR) ] were compared.Results:The positive expression of SPARC protein was significantly higher in HR-positive subgroup than in non-HR-positive subgroup ( χ2=7.28, P<0.05), and was significantly higher in metastasis group than in non-metastasis group ( χ2=7.29, P<0.05). The expression of SPARC protein in HR-positive breast cancer tissues was significantly different between ER and PR groups ( χ2=10.89, 11.08, P<0.05), and there was no statistical significance between the other groups ( χ2=0.25, 0.36, 1.24, 1.10, 2.41, P>0.05) . Conclusion:The expression of SPARC in HR-positive breast cancer tissues is higher, and it is related to clinicopathological characteristics ER and PR and axillary lymph node metastasis.

Objective:To investigate the relationship between expression of secreted protein acidic and rich in cysteine (SPARC) in hormone receptor (HR) -positive breast cancer tissues and clinicopathological characteristics and axillary lymph node metastasis.Methods:The clinical data of 202 patients with breast cancer in Shaanxi Provincial Cancer Hospital were retrospectively analyzed from Mar. 2021 to Mar. 2023. The expression of SPARC protein in the lesion tissues of all subjects at admission was detected by immunohistochemistry. On the basis of molecular typing, the patients were classified into HR-positive subgroup and non-HR-positive subgroup, and the difference in SPARC protein expression in the lesion tissues at admission was compared. According to the axillary lymph node metastasis status at 1 year of follow-up, patients with HR-positive breast cancer were assigned into metastasis group and non-metastasis group, and the expression of SPARC protein in the lesion tissues at admission was compared. HR-positive breast cancer patients were divided into positive group and negative group by means of the expression of SPARC protein at admission. The clinicopathological characteristics [age, tumor size, breast cancer TNM staging, vascular tumor thrombus, histological grading, estrogen receptor (ER), progesterone receptor (PR) ] were compared.Results:The positive expression of SPARC protein was significantly higher in HR-positive subgroup than in non-HR-positive subgroup ( χ2=7.28, P<0.05), and was significantly higher in metastasis group than in non-metastasis group ( χ2=7.29, P<0.05). The expression of SPARC protein in HR-positive breast cancer tissues was significantly different between ER and PR groups ( χ2=10.89, 11.08, P<0.05), and there was no statistical significance between the other groups ( χ2=0.25, 0.36, 1.24, 1.10, 2.41, P>0.05) . Conclusion:The expression of SPARC in HR-positive breast cancer tissues is higher, and it is related to clinicopathological characteristics ER and PR and axillary lymph node metastasis.

【Objective】 To investigate the effect of total flavone of oldenlandia diffusa(FOD) on the stemness, proliferation and apoptosis of breast cancer(BC) stem cells sorted from MDA-MB-231. 【Methods】 Human BC cell lines MDA-MB-231 was cultured in vitro; MDA-MB-231 was stimulated by different concentrations(0 μg/mL, 100 μg/mL, 200 μg/mL and 400 μg/mL) of FOD for different time (24 h, 48 h and 72 h). CCK8 and plate cell cloning assay were used to detect the effect of FOD on MDA-MB-231 proliferation; CD44⁺/CD24^-MDA-MB-231 cell line were tested by flow cytometry and stem cell markers such as Nanog, Oct4 and Sox2 were tested by Western blotting; Annexin V-PE/7-AAD was used to detect the effect of FOD on MDA-MB-231 apoptosis and Bcl2, cleaved-caspase3 and Bax were tested by Western blotting. 【Results】 Cell proliferation of MDA-MB-231 was significantly inhibited by FOD, with the significant suppression at concentrations of 400 μg/mL for 72 h compared with negative control group(P<0.05). The apoptosis rate was significantly upregulated than the negative control group (P<0.05). The protein expression of Bcl2 decreased while Bax and cleaved-caspae3 increased, and stemness markers such as Nanog, Sox2 and Oct4 decreased in FOD-treated cells. Moverover, Akt-GSK3β-β-catenin axis was inhibited in FOD-treated cells. 【Conclusion】 FOD could significantly inhibit the stemness and proliferation and promote the apoptosis of MDA-MB-231.

【Objective】 To investigate the effects of total flavone of oldenlandia diffusa (FOD) on the proliferation and apoptosis of hepatocellular carcinoma (HCC) stem cells sorted from Huh7. 【Methods】 Human HCC cell lines Huh7 was cultured in vitro; CD133 positive (CD133⁺) stem cells in Huh7 cell line were sorted by flow cytometry, and stem cell markers such as Nanog, Oct4 and Sox2 were tested by Western blotting. CD133⁺-Huh7 was stimulated by different concentrations (0 μg/mL, 50 μg/mL, 100 μg/mL and 400 μg/mL) of FOD for different time (24 h, 48 h, 72 h and 96 h). CCK8 and plate cell cloning assay were used to detect the effect of FOD on CD133⁺-Huh7 proliferation while Annexin V-PE/7-AAD was used to detect the effect of FOD on CD133⁺-Huh7 apoptosis. Western blotting was used to detect the protein expressions of protein 53 (P53), factor associated suicide-Fas-associating protein with a novel death domain (Fas-FADD), B-cell lymphoma-2 (Bcl-2), Cleaved-Caspase3, and Bcl-2 associated X protein (Bax). 【Results】 More than 95% of stem cells were purified for further experiments. Cell proliferation of CD133⁺-Huh7 was significantly inhibited by FOD, with the significant suppression at the concentration of 100 μg/mL for 72 h compared with negative control group (P<0.05). The apoptosis rate was significantly upregulated than that in the negative control group (P<0.05). The protein expression of Bcl2 decreased while Bax and Cleaved-Caspae3 increased via FAS/FADDD and P53 axis. 【Conclusion】 FOD can significantly inhibit the proliferation and promote the apoptosis of CD133⁺-Huh7.

Objection: To analyze the factors affecting the prognosis of patients with gastric neuroendocrine neoplasms (G-NENs) by using the surveillance of National Cancer Institute (NCI) of America, Epidemiology and End Results (SEER) database, and to construct a prognostic Nomogram model for individualized prediction of prognosis in patients with G-NENs. Methods: The clinical data of 2720 G-NENs patients with complete follow-up data from 2010 to 2015 in the SEER database were collected. The prognostic Nomogram model was constructed based on independent risk factors determined by survival analysis. The consistency index (C-index) and calibration curve were used to evaluate its accuracy.Area under the curve (AUC) was used to compare the evaluation value between the Nomogram and the 7th edition of AJCC TNM staging. Results: The 1-, 3-, and 5-year survival rates of 2,720 patients with G-NENs were 88.14%, 79.09%, and 71.86%, respectively. Multivariate COX regression analysis showed that gender, age, marital status, other associated tumors, histological type, tumor grade, T stage, M stage, and surgery were independent risk factors affecting survival time of GNENs patients. The C-index of newly constructed Nomogram prediction model was 0.816, which was significantly higher than 0.702 of the 7thAJCC TNM staging (P<0.001), and the 1-, 3- and 5-year calibration curves showed a good agreement between predicted survival and actual survival. The AUC for 1-, 3- and 5-year survival by Nomogram prognostic model was 0.800, 0.811, and 0.820, which was higher than 0.650, 0.688 and 0.698 of the 7th AJCC TNM staging, and the differences were statistically significant (Z= 6.600, 8.085, 9.632, all P<0.0001). Conclusion: The Nomogram prediction model drawn in this study has a high prognostic value and can individually predict the survival rate of G-NENs patients, which is helpful for clinical treatment decision-making and clinical research options.